Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 107

1.

Assessment of Telomere Length, Phenotype, and DNA Content.

Kelesidis T, Schmid I.

Curr Protoc Cytom. 2017 Jan 5;79:7.26.1-7.26.23. doi: 10.1002/cpcy.12.

PMID:
28055113
2.

Weight loss surgery in adolescents corrects high-density lipoprotein subspecies and their function.

Davidson WS, Inge TH, Sexmith H, Heink A, Elder D, Hui DY, Melchior JT, Kelesidis T, Shah AS.

Int J Obes (Lond). 2017 Jan;41(1):83-89. doi: 10.1038/ijo.2016.190.

PMID:
27780977
3.

Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection.

Kelesidis T, Jackson N, McComsey GA, Wang X, Elashoff D, Dube MP, Brown TT, Yang OO, Stein JH, Currier JS.

AIDS. 2016 Nov 13;30(17):2625-2633.

PMID:
27603288
4.

Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s.

Dirajlal-Fargo S, Moser C, Brown TT, Kelesidis T, Dube MP, Stein JH, Currier J, McComsey GA.

Open Forum Infect Dis. 2016 Aug 29;3(3):ofw174.

5.

Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s.

Kelesidis T, Tran TT, Brown TT, Moser C, Ribaudo HJ, Dube MP, Yang OO, McComsey GA, Stein JH, Currier JS.

Antivir Ther. 2016 Sep 23. doi: 10.3851/IMP3093. [Epub ahead of print]

PMID:
27661466
6.

Telmisartan increases vascular reparative capacity in older HIV-infected adults: a pilot study.

Lake JE, Seang S, Kelesidis T, Currier JS, Yang OO.

HIV Clin Trials. 2016 Nov;17(6):225-232.

PMID:
27658740
7.

Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.

Kelesidis T, Moser C, Stein JH, Brown TT, Tran TT, Ribaudo HJ, Dube MP, Yang OO, Currier JS, McComsey GA.

J Infect Dis. 2016 Sep 1;214(5):748-52. doi: 10.1093/infdis/jiw253.

PMID:
27354367
8.

Soluble Levels of Receptor for Advanced Glycation Endproducts (RAGE) and Progression of Atherosclerosis in Individuals Infected with Human Immunodeficiency Virus: ACTG NWCS 332.

Danoff A, Kendall MA, Currier JS, Kelesidis T, Schmidt AM, Aberg JA.

Inflammation. 2016 Aug;39(4):1354-62. doi: 10.1007/s10753-016-0367-6.

PMID:
27216802
9.

Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s.

McComsey GA, Moser C, Currier J, Ribaudo HJ, Paczuski P, Dubé MP, Kelesidis T, Rothenberg J, Stein JH, Brown TT.

Clin Infect Dis. 2016 Apr 1;62(7):853-62. doi: 10.1093/cid/ciw017.

PMID:
26797215
10.

First Report of Ventriculoperitoneal Shunt Infection due to Cyberlindnera fabianii.

Baghdadi J, Hemarajata P, Humphries R, Kelesidis T.

Case Rep Infect Dis. 2015;2015:630816. doi: 10.1155/2015/630816.

11.

The Role of Platelet-Activating Factor in Chronic Inflammation, Immune Activation, and Comorbidities Associated with HIV Infection.

Kelesidis T, Papakonstantinou V, Detopoulou P, Fragopoulou E, Chini M, Lazanas MC, Antonopoulou S.

AIDS Rev. 2015 Oct-Dec;17(4):191-201. Review.

12.

Indications and Types of Antibiotic Agents Used in 6 Acute Care Hospitals, 2009-2010: A Pragmatic Retrospective Observational Study.

Kelesidis T, Braykov N, Uslan DZ, Morgan DJ, Gandra S, Johannsson B, Schweizer ML, Weisenberg SA, Young H, Cantey J, Perencevich E, Septimus E, Srinivasan A, Laxminarayan R.

Infect Control Hosp Epidemiol. 2016 Jan;37(1):70-9. doi: 10.1017/ice.2015.226.

PMID:
26456803
13.

A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness.

Stein JH, Ribaudo HJ, Hodis HN, Brown TT, Tran TT, Yan M, Brodell EL, Kelesidis T, McComsey GA, Dube MP, Murphy RL, Currier JS.

AIDS. 2015 Sep 10;29(14):1775-83. doi: 10.1097/QAD.0000000000000762. Erratum in: AIDS. 2016 Jan;30(2):337.

14.

The safety of polymyxin antibiotics.

Kelesidis T, Falagas ME.

Expert Opin Drug Saf. 2015;14(11):1687-701. doi: 10.1517/14740338.2015.1088520. Review.

PMID:
26365594
15.

Telmisartan to reduce cardiovascular risk in older HIV-infected adults: a pilot study.

Lake JE, Seang S, Kelesidis T, Liao DH, Hodis HN, Stein JH, Currier JS.

HIV Clin Trials. 2015 Oct;16(5):197-206. doi: 10.1179/1945577115Y.0000000006.

16.

In vitro activity of daptomycin in combination with β-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci.

Hindler JA, Wong-Beringer A, Charlton CL, Miller SA, Kelesidis T, Carvalho M, Sakoulas G, Nonejuie P, Pogliano J, Nizet V, Humphries R.

Antimicrob Agents Chemother. 2015 Jul;59(7):4279-88. doi: 10.1128/AAC.05077-14.

17.

Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.

Brown TT, Moser C, Currier JS, Ribaudo HJ, Rothenberg J, Kelesidis T, Yang O, Dubé MP, Murphy RL, Stein JH, McComsey GA.

J Infect Dis. 2015 Oct 15;212(8):1241-9. doi: 10.1093/infdis/jiv194.

18.

Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.

Kelesidis T, Tran TT, Stein JH, Brown TT, Moser C, Ribaudo HJ, Dube MP, Murphy R, Yang OO, Currier JS, McComsey GA.

Clin Infect Dis. 2015 Aug 15;61(4):651-60. doi: 10.1093/cid/civ327.

19.

Substandard/counterfeit antimicrobial drugs.

Kelesidis T, Falagas ME.

Clin Microbiol Rev. 2015 Apr;28(2):443-64. doi: 10.1128/CMR.00072-14. Review.

20.

Assessment of empirical antibiotic therapy optimisation in six hospitals: an observational cohort study.

Braykov NP, Morgan DJ, Schweizer ML, Uslan DZ, Kelesidis T, Weisenberg SA, Johannsson B, Young H, Cantey J, Srinivasan A, Perencevich E, Septimus E, Laxminarayan R.

Lancet Infect Dis. 2014 Dec;14(12):1220-7. doi: 10.1016/S1473-3099(14)70952-1.

PMID:
25455989
Items per page

Supplemental Content

Loading ...
Support Center